Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Acute Postural Effects of Spinal Cord Injury: Dual Neural Opioid and Endocrine Non-Opioid Mechanism
Watanabe, Hiroyuki , Lavrov, Igor , Hallberg, Mathias , Zhang, Mengliang , Zhang, Mengliang , Hallberg, Mathias , Lavrov, Igor , Schouenborg, Jens , Bakalkin, Georgy

Cells | July 2, 2025 | Volume: 14 | Issue: 13 | Pages: 980

10.3390/cells14130980 | PMID 40643501 Get It

Lateral spinal cord injury including lateral hemisection (LHS) leads to asymmetric postural and motor deficits. After traumatic brain injury, asymmetric postural deficits are partly developed through activation of opioid receptors. We here characterized the effects of LHS on hindlimb postural asymmetry (HL-PA), a proxy for neurological impairments, and assessed the involvement of opioid system. In acute experiments on rats, high lumbar LHS induced HL-PA, characterized by ipsilateral hindlimb flexion. This asymmetry persisted after complete spinal cord transection at the hemisection level. Treatment with naloxone, a general opioid antagonist, abolished HL-PA both before and after transection, suggesting that the LHS effects are mediated through opioid receptors and that neuroplasticity of lumbar opioid circuits underlies the persistent asymmetry. Surprisingly, cervical LHS performed after complete lumbar spinal cord transection also led to HL-PA. However, the hindlimb was flexed on the contralateral side, and the effect was resistant to naloxone treatment. This asymmetry may be caused by endocrine factors, which convey side-specific messages through the humoral pathway after their release from supraspinal structures. Thus, after lateral spinal cord injury, the asymmetric postural deficits may be driven by an interplay between opposing lumbar opioid and neuroendocrine non-opioid mechanisms.
Novel Lung Cell-Penetrating Peptide Targets Alveolar Epithelial Type II Cells, Basal Cells, and Ionocytes
Wen, Jin , Singuru, Gajalakshmi, Stiltner, Jeffrey, Mishra, Sanjay , Feldman, Kyle S., McCandless, Kayla, Yurko, Raymond, Islam, Kazi , Frizzell, Raymond A. , Brown, Jonathan M., Zahid, Maliha , Yagi, Hisato , Zahid, Maliha

Pharmaceutics | July 2, 2025 | Volume: 17 | Issue: 7 | Pages: 824

10.3390/pharmaceutics17070824 | PMID 40733033 Get It

Background: Cell-penetrating peptides cross cell membrane barriers while carrying cargoes in a functional form. Our work identified two novel lung-targeting peptides, S7A and R11A. Here, we present studies on biodistribution, the cell types targeted, and an in vitro proof of application. Methods: Studies were performed in human bronchial epithelial cells (HBECs) with and without various endocytic inhibitors, and coincubation with fluorescently labeled transferrin or endocytic markers. Cyclic R11A (cR11A) was conjugated to siRNA duplexes and anti-viral activity against SARS-CoV-2 was tested. Biodistribution studies were performed by injecting wild-type mice with fluorescently labeled peptides, and various circulation times were allowed for, as well as cross-staining of lung sections or isolated single cells with various cellular markers, followed by fluorescence-activated cell sorting or confocal microscopy. Results: cR11A showed peak uptake in 15 min, with the highest uptake in airway epithelial type II (ATII) cells, followed by p63+ basal cells and ionocytes. Cyclization increased transduction efficiencies ~100-fold. Endocytosis studies showed a decrease in peptide uptake by pre-treatment with Pitstop2 but not Amiloride or Nystatin. Endocytic marker Lamp1 showed colocalization at the earliest time point, with the escape of the peptide from endocytic vesicles later. cR11A conjugated to ant-spike and anti-envelop proteins showed anti-viral effects with an EC90 of 0.6 μM and 1.0 µM, respectively. Conclusions: We have identified a novel peptide, cR11A, that targets ATII, basal cells, and ionocytes, the cyclization of which increased transduction efficiency in vitro and in vivo. The uptake mechanism appears to be via clathrin-mediated endocytosis with escape from endocytic vesicles. cR11A can act as a vector to deliver anti-viral siRNA to epithelial cells.
Emerging Trends in Endoscopic Bariatric Therapies: Personalization Through Genomics and Synergistic Pharmacotherapy
Ghusn, Wissam , Divakar, Annika, Abi Mosleh, Kamal , Ghusn, Wissam , Divakar, Annika, Salameh, Yara , Mosleh, Kamal Abi , Storm, Andrew C.

Journal of Clinical Medicine | July 2, 2025 | Volume: 14 | Issue: 13 | Pages: 4681

10.3390/jcm14134681 | PMID 40649055 Get It

Obesity is a major global health challenge associated with significant metabolic and gastrointestinal comorbidities. While metabolic and bariatric surgery remains the gold standard for durable weight loss, the desire for additional options has fueled the development of endoscopic bariatric therapies (EBTs) as another tool for weight loss. This review examines established EBTs, including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGBs), and transoral outlet reduction (TORe), alongside emerging therapies such as duodenal mucosal resurfacing (DMR), incisionless anastomosis creation, and fully automated endoscopic gastric remodeling systems. ESG has demonstrated durable weight loss, favorable safety, and superior cost-effectiveness compared to pharmacotherapy alone, while combination strategies using EBTs and anti-obesity medications (AOMs), particularly GLP-1 receptor agonists, have resulted in greater total-body weight loss than either modality alone. Genetic variation, particularly within the leptin–melanocortin pathway, may predict response to endoscopic interventions and guide personalized treatment selection. Novel investigational procedures such as DMR, automated or robotic gastric remodeling, and magnetic or ultrasound-assisted gastric bypass show promising early results. Endoscopic therapies are poised to become increasingly central to the personalized, scalable management of obesity and related metabolic diseases.
Application of Telemedicine in the Management of Cardiovascular Diseases: A Focus on Heart Failure
Mutirangura, Pornthira , Patel, Dil B. , Akram, Hassan , Hughes, Andrew , Arriola‐Montenegro, Jose , Koukousaki, Despoina , Money, Joel , Meyer, Mikhail , Harata, Mikako , Tóth, András , Alexy, Tamás , Patel, Dil , Meyer, Mikhail , Harata, Mikako , Alexy, Tamas , Hughes, Andrew M , Kosmopoulos, Marinos

Reviews in Cardiovascular Medicine | July 2, 2025 | Volume: 26 | Issue: 6 | Pages: No page available

10.31083/rcm37835 | PMID 40630466 Get It

Heart failure (HF) is a complex clinical syndrome that represents one of the leading causes of morbidity and mortality in developed nations. It is well established that every HF-related hospital admission leads to worsened quality of life for the patient and their caregiver and also imposes a significant financial burden on society. Therefore, reducing hospital admissions for this population has emerged as a critical tactic over the past decades. Initial attempts at remote monitoring focused on self-reported vital signs and symptoms, yet these proved ineffective. Meanwhile, subsequent technological advancements have enabled the development of miniature sensors capable of detecting and monitoring a wide range of physiologically relevant parameters; some of these advancements have been integrated into implantable devices, such as pacemakers and defibrillators. However, noninvasive monitoring has recently emerged as an alternative option for patients with HF, offering early congestion detection without requiring an invasive procedure. This review aims to summarize implanted and noninvasive devices, their characteristics, monitored parameters, and potential limitations and challenges around their integration into routine clinical practices.
Cannabis use in Patients With Inflammatory Bowel Disease is Associated With Longer Endoscopic Duration and Endoscopic Inflammation
Loeb, Lauren , Hochwald, Alexander , Picco, Michael F., Chan, Johanna , Kinnucan, Jami , Chan, Johanna L, Kinnucan, Jami A., Hashash, Jana G. , Chadha, Ryan , Farraye, Francis A.

Crohn's & Colitis 360 | July 2, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/crocol/otaf034 | PMID 40667460 Get It

Abstract Background Patients with inflammatory bowel disease (IBD) often experience symptoms refractory to available treatments, prompting the use of alternative therapies like cannabis. Previous studies have shown cannabis users require higher levels of sedation for procedures. The anti-inflammatory effects of cannabis have been studied with mixed conclusions. We aimed to investigate if patients with IBD who reported cannabis use required more resources for endoscopic procedures and were more likely to have endoscopic inflammation. Methods This is a retrospective case–control study of adult patients with IBD between November 2018 and November 2022 at a tertiary academic medical center undergoing endoscopic evaluation of acute complaints related to IBD. Cases were matched for age, sex, and body mass index. Results There were 124 patients with IBD with 62 patients reporting cannabis use and 62 patients without reported cannabis use. There was a significant difference in endoscopy duration (P < .001) and endoscopic inflammation (P = .044) between groups. There was no significant difference in recovery room length of stay (P = .15), IBD treatment during time of endoscopy (P = .84), stricture (P = .53), propofol dose administered when adjusted for procedure duration (P = .082), or endoscopic duration between cannabis users with and without endoscopic inflammation (P = .194). Conclusions IBD cannabis users had longer endoscopic durations and were more likely to exhibit inflammation on endoscopic evaluation compared to cannabis non-users. Our study underscores the importance of medication reconciliation for more accurate resource allocation. Additionally, federal expansion of cannabis research is needed for randomized control trials to fulfill the presently unmet need for data on patient outcomes.
Ultrafiltration during cardiopulmonary bypass: An ongoing overall fluid challenge
Neal, James R. , Blau, Caitlin, Blau, Caitlin L

Perfusion | July 2, 2025 | Volume: 41 | Issue: 3 | Pages: 362-364

10.1177/02676591251356415 | PMID 40599093 Get It

A Logarithmic Compression Method for Magnitude-Rich Data: The LPPIE Approach
Alevizos, Vasileios , Yue, Zongliang , Edralin, Sabrina , Xu, Clark , Gerolimos, Nikitas , Papakostas, George A. , Georlimos, Nikitas , Yue, Zongliang , Edralin, Sabrina , Xu, Clark , Papakostas, George A

Technologies | July 2, 2025 | Volume: 13 | Issue: 7 | Pages: 278

10.3390/technologies13070278 Get It

This study introduces Logarithmic Positional Partition Interval Encoding (LPPIE), a novel lossless compression methodology employing iterative logarithmic transformations to drastically reduce data size. While conventional dictionary-based algorithms rely on repeated sequences, LPPIE translates numeric data sequences into highly compact logarithmic representations. This achieves significant reduction in data size, especially on large integer datasets. Experimental comparisons with established compression methods—such as ZIP, Brotli, and Zstandard—demonstrate LPPIE’s exceptional effectiveness, attaining compression ratios nearly 13 times superior to established methods. However, these substantial storage savings come with elevated computational overhead due to LPPIE’s complex numerical operations. The method’s robustness across diverse datasets and minimal scalability limitations underscore its potential for specialized archival scenarios where data fidelity is paramount and processing latency is tolerable. Future enhancements, such as GPU-accelerated computations and hybrid entropy encoding integration, are proposed to further optimize performance and broaden LPPIE’s applicability. Overall, LPPIE offers a compelling alternative in lossless data compression, substantially redefining efficiency boundaries in high-volume numeric data storage.
Enhancing ultrasonographic detection of hepatocellular carcinoma with artificial intelligence: current applications, challenges and future directions
Wongsuwan, Janthakan , Nirattisaikul, Sitang , Cheungpasitporn, Wisit, Kaewdech, Apichat , Cheungpasitporn, Wisit , Kaewdech, Apichat , Cheungpasitporn, Wisit , Tubtawee, Teeravut , Danpanichkul, Pojsakorn , Chaichulee, Sitthichok

BMJ Open Gastroenterology | July 1, 2025 | Volume: 12 | Issue: 1 | Pages: e001832

10.1136/bmjgast-2025-001832 | PMID 40592728 Get It

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with early detection playing a crucial role in improving survival rates. Artificial intelligence (AI), particularly in medical image analysis, has emerged as a potential tool for HCC diagnosis and surveillance. Recent advancements in deep learning-driven medical imaging have demonstrated significant potential in enhancing early HCC detection, particularly in ultrasound (US)-based surveillance. This review provides a comprehensive analysis of the current landscape, challenges, and future directions of AI in HCC surveillance, with a specific focus on the application in US imaging. Additionally, it explores AI’s transformative potential in clinical practice and its implications for improving patient outcomes. We examine various AI models developed for HCC diagnosis, highlighting their strengths and limitations, with a particular emphasis on deep learning approaches. Among these, convolutional neural networks have shown notable success in detecting and characterising different focal liver lesions on B-mode US often outperforming conventional radiological assessments. Despite these advancements, several challenges hinder AI integration into clinical practice, including data heterogeneity, a lack of standardisation, concerns regarding model interpretability, regulatory constraints, and barriers to real-world clinical adoption. Addressing these issues necessitates the development of large, diverse, and high-quality data sets to enhance the robustness and generalisability of AI models. Emerging trends in AI for HCC surveillance, such as multimodal integration, explainable AI, and real-time diagnostics, offer promising advancements. These innovations have the potential to significantly improve the accuracy, efficiency, and clinical applicability of AI-driven HCC surveillance, ultimately contributing to enhanced patient outcomes.
Who Reconstitutes the Chemotherapy? The Educational and Practice Needs of Oncology Pharmacists in West Africa: A Call for Multidisciplinary Team Approach in Oncology Care
Chidebe, Runcie C.W. , Alabelewe, Ramatu Masud, Sapkota, Krishna Prasad , Esiaka, Darlingtina , Okwu, Gloria C., Emejulu, Jacinta, Umar, Adamu Abubakar , Okwuegbunam, Ndifreke, David, Funsho, Adepoju, Toyosi, Agha, Agha A., Ugwu, Ejike, Aruah, Simeon Chinedu , Duncombe, Rob, Wannang, Noel N., O’Bryant, Cindy L. , Esiaka, Darlingtina K , Aruah, Simeon C , Babalola, Peace C , Harvey, R Donald , O'Bryant, Cindy , Odedina, Folakemi , Nwakasi, Candidus C. , Umar, Adamu A., Mshelia, Richard, Harvey, R. Donald

JCO Global Oncology | July 1, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-25-00021 | PMID 40591900 Get It

PURPOSE Oncology pharmacists (OPs) play a crucial role in cancer care, treatment, survivorship, and multidisciplinary teams (MDTs). OPs have specialized training in designing, administering, monitoring, and modifying oncology chemotherapy; managing adverse events; and evaluating clinical trials and investigational drugs. Yet, the state of OP has remained largely unknown in the clinical oncology workforce of the West African region. Therefore, this study aimed to understand who reconstitutes chemotherapy and to explain the OP educational and practice needs, challenges, and solutions in Nigeria. MATERIALS AND METHODS Using a concurrent embedded mixed method design, 35 OPs completed a questionnaire, and 12 others responded to a semistructured interview. The data were then subjected to inductive thematic and descriptive analyses. RESULTS The findings showed that 54% of the OPs were responsible for chemotherapy reconstitution, and only 60% of the oncology centers had a biosafety cabinet. 91% of OPs were practicing; however, only 54% were trained in OP, and none of the OPs were board-certified. Most of the OPs spent time weekly on reconstitution, administrative duties, teaching, and training; only 3% spent on oncology clinical trials and conferences and 8% on noninterventional research. We identified four themes: (1) Some OPs are not reconstituting chemotherapy: A Call for MDT, (2) For OP, No Training is Enough, (3) Board Certification will give OPs Recognition, and (4) Introduction of OP Course in Universities. CONCLUSION To improve patient treatment outcomes, training on chemotherapy reconstitution should be prioritized, integration of OPs into MDTs, and the safe handling of chemotherapy in centers should be mandated in the region. The West African Postgraduate College of Pharmacists should be supported in expanding its curriculum and introducing OP fellowships.
Long-Term Autoimmune Polyarthritis due to COVID-19 Vaccine
Pallipamu, Namratha, Pandit, Trupiti, Pandit, Ramesh

HCA Healthcare Journal of Medicine | July 1, 2025 | Volume: 6 | Issue: 3 | Pages: No page available

10.36518/2689-0216.1619 | PMID 40642580 Get It

Background Vaccinations for COVID-19 have played a pivotal role in controlling the global pandemic, with most adverse events being mild and transient. However, rare post-vaccination autoimmune responses have been reported. The understanding of long-term rheumatologic sequelae, particularly autoimmune polyarthritis following COVID-19 vaccination, remains limited. Case Presentation We report the case of a 41-year-old previously healthy man who developed progressive polyarthritis and systemic symptoms following the Johnson & Johnson COVID-19 vaccine. The initial symptoms of joint swelling and arthralgia appeared within a week of the first vaccine dose, subsiding temporarily with medication. After receiving a booster dose, the patient experienced worsening polyarthritis affecting multiple joints including knees, elbows, wrists, shoulders, and neck, along with low-grade fever, fatigue, and functional decline. Despite outpatient anti-inflammatory therapy, symptoms persisted and worsened over the next six months, prompting hospitalization. Workup revealed elevated inflammatory markers (ESR 77 mm/hr, CRP 193.2 mg/L), synovial fluid consistent with inflammatory arthritis, and infectious serologies. Imaging showed joint effusions and calcified pulmonary granulomas. He was diagnosed with vaccine-induced reactive arthritis. Treatment with intravenous corticosteroids led to partial symptom relief, and he was discharged on oral steroids and initiated on methotrexate for long-term management. Conclusion Clinicians should maintain a high index of suspicion for autoimmune phenomena such as reactive polyarthritis following COVID-19 vaccination, especially in patients with new-onset joint symptoms. Early recognition and referral to rheumatology may improve outcomes. Further studies are needed to clarify the pathophysiology, risk factors, and long-term prognosis of such vaccine-associated autoimmune conditions.